Y-mAbs Therapeutics, Inc. Operating Expenses
Y-mAbs Therapeutics, Inc. reported Operating Expenses of $32.64 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-11-05
- Y-mAbs Therapeutics, Inc. operating expenses for the quarter ending 2020-09-30 was $32.64M, a 34.00% increase year-over-year.
- Y-mAbs Therapeutics, Inc. operating expenses for the quarter ending 2020-06-30 was $40.45M, a 117.09% increase year-over-year.
- Y-mAbs Therapeutics, Inc. operating expenses for the quarter ending 2020-03-31 was $26.75M, a 64.57% increase year-over-year.
- Y-mAbs Therapeutics, Inc. operating expenses for the quarter ending 2019-12-31 was $23.76M, a 68.76% increase year-over-year.
- Y-mAbs Therapeutics, Inc. operating expenses for fiscal 2019 was $83.00M, a 92.01% increase from fiscal 2018.
- Y-mAbs Therapeutics, Inc. operating expenses for fiscal 2018 was $43.23M, a 124.64% increase from fiscal 2017.
- Y-mAbs Therapeutics, Inc. operating expenses for fiscal 2017 was $19.24M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-09-30 | $32.64M 10-Q · filed 2020-11-05 | $73.09M derived: sum of 2 quarters · filed 2020-11-05 | $99.84M 10-Q · filed 2020-11-05 | $123.60M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | $40.45M 10-Q · filed 2020-08-06 | $67.20M 10-Q · filed 2020-08-06 | $90.96M derived: sum of 3 quarters · filed 2020-08-06 | $115.32M derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-03-31 | $26.75M 10-Q · filed 2020-05-07 | $50.51M derived: sum of 2 quarters · filed 2020-05-07 | $74.86M derived: sum of 3 quarters · filed 2020-11-05 | $93.50M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-12-31 | $23.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $48.12M derived: sum of 2 quarters · filed 2020-11-05 | $66.75M derived: sum of 3 quarters · filed 2020-11-05 | $83.00M 10-K · filed 2020-03-12 |
| 2019-09-30 | $24.36M 10-Q · filed 2020-11-05 | $42.99M derived: sum of 2 quarters · filed 2020-11-05 | $59.25M 10-Q · filed 2020-11-05 | $73.32M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $18.63M 10-Q · filed 2020-08-06 | $34.89M 10-Q · filed 2020-08-06 | $48.97M derived: sum of 3 quarters · filed 2020-08-06 | $60.38M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $16.25M 10-Q · filed 2020-05-07 | $30.33M derived: sum of 2 quarters · filed 2020-05-07 | $41.75M derived: sum of 3 quarters · filed 2020-05-07 | $52.00M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $14.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $25.49M derived: sum of 2 quarters · filed 2020-03-12 | $35.75M derived: sum of 3 quarters · filed 2020-03-12 | $43.23M 10-K · filed 2020-03-12 |
| 2018-09-30 | $11.41M 10-Q · filed 2019-11-13 | $21.67M derived: sum of 2 quarters · filed 2019-11-13 | $29.15M 10-Q · filed 2019-11-13 | $38.43M derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | $10.26M 10-Q · filed 2019-08-14 | $17.74M 10-Q · filed 2019-08-14 | $27.01M derived: sum of 3 quarters · filed 2019-08-14 | $30.85M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $7.48M 10-Q · filed 2019-05-10 | $16.75M derived: sum of 2 quarters · filed 2019-05-10 | $20.60M derived: sum of 3 quarters · filed 2019-05-10 | |
| 2017-12-31 | $9.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $13.12M derived: sum of 2 quarters · filed 2019-03-22 | $19.24M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $3.84M 10-Q · filed 2018-11-13 | $9.97M 10-Q · filed 2018-11-13 |